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Oxidative stressAbstract Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by
increased inflammation of synovial joint. The collagen-induced arthritis (CIA) is a widely used ani-
mal model for RA. Spironolactone possesses potent anti-inflammatory and immune modifying
properties that might make it an excellent medical intervention for rheumatic diseases.
Aim of the work: The present study was conducted to evaluate the therapeutic effect of spirono-
lactone (SPIR) in collagen-induced arthritis model in mice.
Materials and methods: DBA/1mice were divided into eight groups and CIA mice treated with
SPIR (20, 40 and 80 mg/kg/day), methotrexate (MTX) and vehicle was administered beginning
on day 21 (arthritis onset) until day 42. The effects of treatment in the mice were assessed by clinical,
oxidative markers, inflammatory cytokines; tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-
6) as well as histological changes in ankle joints.
Results: Mice immunized with collagen II with complete and incomplete Freund’s adjuvant
developed inflammatory arthritis. Spironolactone (40 and 80 mg/kg/day) was effective in bringing
significant changes on all the parameters (paw swelling, arthritis score, oxidative markers) studied.
Oral administration of SPIR significantly reduced the level of TNF-a and IL-6. The protective
effect of SPIR against RA was also evident from the ankle joint histopathology and its effect
was found comparable to that of MTX.
Conclusion: Amelioration of paw swelling, antioxidant properties, inflammatory mediators
TNF-a and IL-6 and histopathological changes indicates that SPIR can be considered with
MTX among the treatment armamentarium of arthritis. Spironolactone may be considered for
use as a novel therapeutic treatment against human arthritis.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is an autoimmune and chronic
inflammatory disorder which results in inflammation of multi-
ple joints with subsequent destruction of joint cartilage andgyptian
2 I. Verma et al.erosive destruction of bone with evolving treatment strategies
[1]. RA is a potentially devastating condition which lacks good
treatment options. Although a number of synthetic disease-
modifying antirheumatic drugs (DMARDs) are used for the
clinical treatment of RA, an effective drug with few side effects
and of low cost is still lacking [2–4]. Now a days, much atten-
tion has been focused on biologic agents as anti-tumor necrosis
factor-a (anti-TNF-a), interleukin-6 (IL-6) and IL-1 that inhi-
bit the activity of proinflammatory cytokines, which are
believed to play a primary role in joint destruction [5]. Biologic
DMARD therapy seems to be even more effective than syn-
thetic DMARDs in RA, ankylosing spondylitis (AS) and pso-
riatic arthritis (PsA) [5,6]. Despite their efficacy, biologic
DMARDs have major limitations as parenteral administra-
tion, risk of infection, neutralizing antibodies and the cost
[3,7]. Due to the chronic nature of disease and side effects asso-
ciated with these drugs, patients with RA rely on other option
like use of complementary and alternative safe, economical
and acceptable oral therapeutic agents for treating arthritis
to achieve remission and to prevent collateral damage.
Spironolactone was first known to possess anti-
inflammatory potential as early as 1961 [8]. However, that
observation seemed to have gone largely unnoticed until the
last few years. However, in a Danish study population
spironolactone significantly reduced the proinflammatory
cytokines as well as decreased gene transcription for many reg-
ulators of inflammation and also demonstrated reduction in
interferon system in incubated human whole blood in arthritis
patients [9]. In 2006, Miura et al. reported the potential anti-
inflammatory effect of spironolactone for reduction in
inflammation-related cardiovascular risk factors [10]. In
another study, the immunomodulatory and anti-
inflammatory properties of spironolactone have been shown
in autism [11]. Several researchers have shown that spironolac-
tone has the potential to improve endothelial dysfunction in
RA, AS and polycystic ovary syndrome [12–14] and to atten-
uate alleviated oxidative stress [15,16]. This is relevant because
oxidative stress has been well described in RA [17–19]. Despite
its widespread use in the treatment of different disorders, there
is no dearth of scientific evidence regarding its anti-
inflammatory, immunomodulatory and antioxidant activity
in experimental animal model of arthritis.
In view of above research, the present study was carried out
to evaluate the immunomodulatory and anti-inflammatory
effect of spironolactone on type II collagen-induced arthritis
(CIA) in DBA/1 mice. Collagen-induced arthritis model is
the most extensively studied autoimmune model of RA. It is
induced by immunization with an emulsion of complete Fre-
und’s adjuvant (CFA) and type II collagen (CII) [20].
2. Materials and methods
2.1. Animals
DBA/1 mice (7–10 weeks of age) were purchased from Central
Drug Research Institute (CDRI), Lucknow, India. The ani-
mals were housed in a controlled environment and provided
with standard rodent chow and distilled water. The experimen-
tal protocol was approved by Institutional Animal EthicsPlease cite this article in press as: Verma I et al. Therapeutic eﬀects of spironolacto
Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.06.002Committee (IAEC) and animal care was done in compliance
with Committee for the purpose of control and Supervision
of Experimental on Animals (CPCSEA) regulations on the
protection of animals used for experimental and other scien-
tific purposes (Reg. No- 107/99/CPCSEA).
2.2. Reagents and drugs
Bovine type II collagen (CII), CFA and Freund’s incomplete
adjuvant (FIA) were purchased from Sigma Aldrich Co., St.
Louis, MO, USA. Spironolactone (SPIR) and methotrexate
(MTX) were obtained from R.P.G life Sciences, Mumbai,
India and Cadila Pharmaceutical Ltd., Mumbai, India, respec-
tively. All the reagents used in the present study were of ana-
lytical grade.
2.3. Collagen-induced arthritis (CIA)
Bovine type II collagen was dissolved overnight at 4 C in
0.01M acetic acid at a concentration of 2 mg/ml. For the
induction of CIA, mice were immunized with 100 lg of bovine
CII in CFA containing 4 mg/ml heat-killed mycobacterium
tuberculosis by 50 ll volume intradermal injection at the base
of the tail of DBA/1 mice on day 0. On day 21st, a booster
injection of CII in FIA was administered at the base of the tail,
but proximal to the primary injection site [20].
2.4. Experimental protocol
In total, forty-eight DBA/1 mice were randomly divided into
eight groups each comprising six animals. Group I and group
II served as normal control and arthritic control/positive con-
trol. Groups III–V arthritic mice were treated orally with SPIR
20, 40 and 80 mg/kg/day, respectively given for 21 days after
the administration of booster injection of CII in FIA. Group
VI arthritic mice treated with MTX (5 mg/kg/week). Groups
VII and VIII arthritic mice were treated with carboxymethyl
cellulose (CMC) (SPIR groups) and phosphate buffered saline
(PBS) (MTX group) respectively and served as a vehicle con-
trol. The animals of different groups were sacrificed by cervical
decapitation. The blood samples from all groups were col-
lected from the orbital vein at the end of experiment for oxida-
tive markers and inflammatory mediators. The levels of
oxidative stress markers including glutathione (GSH),
superoxide-dismutase (SOD), thiobarbituric acid reactivity
(TBARS) and nitric oxide were determined.
2.5. Evaluation of arthritis
To evaluate the incidence and severity of arthritis, mice were
examined 3 times/week. The severity of arthritis was scored
on a 4-point scale, in which 0 = normal appearance, 1 = ery-
thema and/or mild swelling, 2 = erythema and/or moderate
swelling, and 3 = erythema and moderate swelling extending
from the ankle to metatarsal joints, and 4 = erythema and sev-
ere swelling encompass the ankle, foot and digits, or ankylosis
of the limb. An arthritis score for each mice was calculated by
the sum of the four paws. The joint diameter was measured byne on a collagen-induced arthritis model of rheumatoid arthritis, The Egyptian
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left hind paws [20].
2.6. Measurement of serum TNF-a and IL-6
Were measured in mouse serum using enzyme-linked
immunosorbent assay (ELISA) method. TNF-a and IL-6 were
estimated by ELISA kit (Ray biotech Inc. Parkway Lane, Suite
100, Norcross GA) according to the manufacturer’s instruc-
tions. The lower limit of detection was 10 pg/ml. Their concen-
trations were expressed in pg/ml.
2.7. Histopathology
Mice were sacrificed at the end of experiment; the ankle joints
were removed and fixed in 10% formalin, then decalcified and
embedded in paraffin. The knee joints were sliced and stained
with hematoxylin and eosin (H and E). Histopathological
changes were analyzed under a light microscope. The inflam-
matory changes were assessed in the arthritis control as well
as in the drug treated arthritic mice. Analysis of histopathol-
ogy was observed in a blind manner by 2 independent
pathologists.
2.8. Statistical analysis
Results were expressed as mean ± standard error of mean
(SEM). The significance of the differences of the mean values
with respect to positive control was analyzed using a one-
way analysis of variance (ANOVA) followed by post hoc anal-
ysis. All statistical analysis was performed using Graph pad
prism Version 6.0 (Graph pad prism, San Diego, CA, USA).
The p-value <0.05 was considered statistically significant
(*p 6 0.05, **p 6 0.01 and ***p 6 0.001 vs. arthritis control).
3. Results
3.1. Changes in arthritis score and paw thickness
Arthritis symptoms were first observed about 3 weeks after ini-
tial immunization of mice with CII (Fig. 1A). The arthritis
score was taken as the main parameter of arthritis disease
between the different treatment groups. Arthritis mice treated
with SPIR significantly inhibited diseases severity compared
with the positive control group (p< 0.05). In the arthritic mice
group treated with high dose (80 mg/kg) of SPIR, there was
marked reduction of arthritis score (p< 0.001) and when trea-
ted with lower dose of SPIR (20/40 mg/kg) (Fig. 1). The arthri-
tis score of SPIR 80 group was slightly higher than that of the
MTX group, suggesting that the therapeutic effect of SPIR 80
on CIA was almost similar as MTX. There was no change in
arthritis score in PBS and CMC groups. At the end of exper-
iment, paw thickness was significantly lower in the SPIR (40
and 80 mg/kg/day) compared with positive control (Fig. 1B).
Mice treated with SPIR 20 had slightly thinner paws, but
not the significant difference compared with positive control
group. The inhibitory effect of SPIR 80 group (66%) was com-
parable to that of MTX where 74% inhibition in paw thickness
was observed.Please cite this article in press as: Verma I et al. Therapeutic eﬀects of spironolacton
Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.06.0023.2. Effect of drugs on serum cytokines (Fig. 2)
A substantial increase in the production of TNF-a and IL-6
was found in mice with CIA compared with normal control
group on day 42. The serum level of TNF-a and IL-6 were sig-
nificantly reduced in SPIR 40 (all p< 0.05), SPIR 80 (all
p 6 0.01) and MTX (all p 6 0.01) treated mice groups com-
pared with positive control group. The effect of SPIR 80
(36%) was slightly higher than MTX where 25% reduction
in levels of TNF-a was observed, while the effect of SPIR 80
group (27%) on the reduction of IL-6 level was almost similar
to MTX (31%) treated mice.
3.3. Effects of drugs on parameters of oxidative markers and
nitric oxide (Fig. 3)
Induction of arthritis in the positive control group produced a
marked reduction in the levels of GSH and SOD compared
with normal control. Treatment of arthritic mice with SPIR
40 and 80 significantly (p< 0.05) increased the levels of
GSH. Like glutathione, the SOD activity significantly
increased in SPIR 40 (p< 0.05) and 80 (p 6 0.01) treated mice
groups. TBARS level was significantly higher in positive con-
trol group compared to the normal control. Spironolactone
(SPIR 40 and 80, p 6 0.01) significantly reduced levels of
TBARS. Level of NO was higher (p 6 0.01) in the positive con-
trol group than normal control. The level of NO significantly
reduced in both spironolactone (SPIR 40, p< 0.05 and 80,
p 6 0.01) and MTX (p< 0.05) treated mice. In MTX treated
group, there was no statically change in the levels of GSH,
SOD and TBARS.
3.4. Histological findings (Fig. 4)
Results of histopathology of the ankle joints of all experimen-
tal groups are demonstrated in Fig. 4 as analyzed by patholo-
gists. It was clearly indicated that the ankle joints of DBA/1
mice in the control group exhibited no pathological changes
(Fig. 4A) However, staining revealed multiple pathological
changes in the arthritis control group (Fig. 4B), including car-
tilage degradation, bone destruction and inflammatory cell
infiltration. Treatment with MTX produced a marked reduc-
tion in cartilage degradation, bone destruction and inflamma-
tory cell infiltration compared (Fig. 4C) with arthritis control.
Similar attenuation of these parameters was also observed with
high dose of spironolactone (SPIR 80) treated mice (Fig. 4F).
In the SPIR 40 group, infiltration of synovial cells was present
and moderate cartilage degradation and bone destructive
change was observed (Fig. 4E). There was no significant differ-
ence of synovial cells infiltration, cartilage and bony destruc-
tive changes in the SPIR 20 (Fig. 4D), PBS and CMC
control groups (Figure not shown).
4. Discussion
Several anti-inflammatory drugs are known to treat arthritis,
joint swelling and to improve joint functions. Spironolactone
is a potassium sparing diuretic that has shown immunomodu-
latory, anti-inflammatory and antioxidant properties with ae on a collagen-induced arthritis model of rheumatoid arthritis, The Egyptian
Figure 1 (A) Arthritis scores of collagen-induced arthritis (CIA) and normal mice in different study groups. (B) Paw thickness of normal
and CIA mice after treatment. NC: normal control, PC: positive/arthritis control, MTX: methotrexate control, SPIR: spironolactone (20/
40/80 mg/kg/day). Values are given as mean ± SEM (n = 6), **p 6 0.01 and ***p 6 0.001 vs. arthritis control.
Figure 2 Reduction of tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) level in collagen-induced arthritis mice by
spironolactone and methotrexate treatment. All the values are the mean and SEM. *p< 0.05, **p 6 0.01 compared with positive control
group.
4 I. Verma et al.potential to improve endothelial dysfunction [9,11–14]. In view
of the pleiotropy exhibited by SPIR and their anti-
inflammatory property, the present study was carried out to
evaluate the effect of SPIR on the clinical, biochemical and his-
tological parameters in the experimental mice model of CIA.
CIA is a well established animal model widely used for phar-
macological evaluation of anti-arthritic agents, as it possesses
many immunological and pathological similarities to human
RA and therefore is widely utilized as an animal model of
RA. In the present study, DBA/1 mice were used to establish
the model.
In the present study, the arthritis score of the SPIR group
was slightly higher than that of the MTX group, however, a
marked reduction in the arthritis score was observed than
the positive control. Treatment with arthritic mice with SPIR
40 was also significantly lower than that of the positive controlPlease cite this article in press as: Verma I et al. Therapeutic eﬀects of spironolacto
Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.06.002group. This suggests that, similarly to MTX, SPIR possesses
the potential to treat RA. MTX is the most commonly used
as a synthetic disease modifying anti-rheumatic drug
(DMARD) and has immunomodulatory and anti-
inflammatory effects [21]. Although, there are several disad-
vantages, including the adverse effects and significant numbers
of patients require additional treatments in order to control
the disease process, either concurrently, or following treatment
with MTX.
The serum cytokines measured in the present study were
TNF-a and IL-6. There is plenty of evidence that key cytokines
(TNF-a and IL-6) contribute to the inflammation in the patho-
genesis of RA [22–25]. The results showed that, following
treatment with MTX and SPIR (40 and 80), TNF- a and IL-
6 significantly recovered as compared to model group. How-
ever, the reduction of TNF- a in SPIR treated mice is slightlyne on a collagen-induced arthritis model of rheumatoid arthritis, The Egyptian
Figure 3 Effect of spironolactone and methotrexate on the levels of oxidative markers in collagen-induced arthritis mice treated with
SPIR 20, 40 and 80 mg/kg/day and MTX 5 mg/kg/week for 3 weeks. SPIR 80 produced significant effect on glutathione (GSH),
superoxide dismutase (SOD)), thiobarbituric acid reactivity (TBARS) and nitric oxide (NO) level. MTX does not have shown any
significant change in GSH, SOD and TBARS but significantly reduced NO level (p< 0.05). Values are given as mean ± SEM (n= 6).
*p< 0.05, **p 6 0.01.
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modulate the progression of RA via regulation of these pro-
inflammatory cytokines through inhibition of nuclear factor
jB (NF-jB). NF-jB is one of the most important regulators
of proinflammatory cytokines i.e. TNF-a, IL-6, IL-1b and
IL-8, regulates osteoclastic differentiation and participate in
the chronic inflammatory processes that often aggravate bone
loss, such as RA [26,27]. The increased level of NF-jB has
been demonstrated in the CIA animal model and it gradually
increases during the evolution of disease [28]. NF-kB has been
demonstrated as a potential therapeutic target to control
inflammation. More recently, it has been shown that spirono-
lactone inhibits production of proinflammatory mediators via
inactivation of NF-jB [29–31]. Inhibition of NF-jB is inde-
pendent of the mineralocorticoid receptor (MR), not only
MR, but also androgen receptor or progesterone receptor
[29,31].
In the current study, histopathological changes revealed by
bone erosion, cartilage destruction and marked cellular infil-
tration of the CIA mice treated with MTX significantly
improved. We also found that SPIR (80 mg/kg/day) almost
completely prevented joint destruction, bone erosion and car-Please cite this article in press as: Verma I et al. Therapeutic eﬀects of spironolacton
Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.06.002tilage degradation in CIA mice, almost unanimously corre-
sponding to the MTX group suggesting that SPIR may also
exhibit immunomodulatory and anti-inflammatory properties.
The role of antioxidant in the treatment of chronic inflam-
matory arthritis has been investigated by several researchers
[17,32–37]. Formation of reactive oxygen species (ROS) and
reactive nitrogen species as a result of disease activity may play
an important role. Oxidative stress, decreased antioxidant sta-
tus and increased NO are the hallmarks in RA patients [32],
which lead to connective tissue degradation leading to joint
and periarticular deformities in RA [17]. Increased level of
ROS and NO has a role in the activation of transcription fac-
tors such as NF-jB [35]. Our study, showed that SPIR (40 and
80 mg/kg/day) treatment, was associated with significant
improvement in GSH and SOD and a significant reduction
in levels of TBARS and NO, but in MTX treated mice group
has not shown any significant change in oxidative markers
except NO. Our study results suggested that SPIR may have
anti inflammatory and antioxidant potential to treat RA and
are in agreement with earlier studies that reported anti-
inflammatory and antioxidant effect of spironolactone in var-
ious diseases [15,16,38,39].e on a collagen-induced arthritis model of rheumatoid arthritis, The Egyptian
Figure 4 Histopathological images of the ankle joint of DBA1 mice in different experimental groups. (A) Normal control group: normal
bone, cartilage and joint tissue. (B) Arthritis control group: infiltration of inflammatory cells, erosive bone and cartilage destruction. (C)
Methotrexate treated group: no infiltration of inflammatory cells with minimal cartilage destruction and inflammation. (D)
Spironolactone 20 treated group: erosive bone and cartilage destruction showing marked infiltration of inflammatory cells in synovial
tissue. (E) Spironolactone 40 treated group: moderate erosive bone and cartilage destruction with moderate infiltration of inflammatory
cells in synovial tissue. (F) Spironolactone 80 treated group: mild infiltration of inflammatory cells in the synovial tissue. There is no bone
and cartilage destruction.
6 I. Verma et al.5. Conclusion
The current study highlights that anti-inflammatory and
immunomodulatory effect of SPIR has extremely similar ther-
apeutic effects to MTX, suggesting that SPIR may be a poten-
tial alternative DMARD for the treatment of RA. However,
further pharmacological investigations at a molecular level to
establish the mechanism of the action of the drug are war-
ranted. Furthermore, studies on the toxicity of SPIR are
required to demonstrate the clinical applications of this
therapy.Conﬂict of interest
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